Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure

JACC: Heart Failure

Volumn 3, Issue 2, 2015, Pages 136-145

  Dei Cas, Alessandra ^a   Khan, Sadiya S ^b   Butler, Javed ^c   Mentz, Robert J ^d   Bonow, Robert O ^b   Avogaro, Angelo ^e   Tschoepe, Diethelm ^f   Doehner, Wolfram ^g   Greene, Stephen J ^b   Senni, Michele ^h   Gheorghiade, Mihai ^b   Fonarow, Gregg C ⁱ  

^a UNIVERSITY OF PARMA   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PADOVA   (Italy)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

ⁱ UCLA MEDICAL CENTER   (United States)

Author keywords

Diabetes mellitus; Diabetic cardiomyopathy; Heart failure

Indexed keywords

ALISKIREN; ALOGLIPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; GLITAZONE DERIVATIVE; INSULIN GLARGINE; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; MINERALOCORTICOID ANTAGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL; FATTY ACID;

ACUTE HEART FAILURE; AUTONOMIC NEUROPATHY; DIABETES MELLITUS; DIURESIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FLUID RETENTION; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY FAILURE; LOW DRUG DOSE; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CARDIAC MUSCLE; DRUG EFFECTS; HEART; HEART MITOCHONDRION; METABOLISM; PHYSIOLOGY; VASCULAR REMODELING;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETES MELLITUS; DIURETICS; FATTY ACIDS, NONESTERIFIED; HEART; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA, HEART; MYOCARDIUM; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; VASCULAR REMODELING;

EID: 84922016269     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.08.004     Document Type: Review

References (54)

1. Sarma S., Mentz R.J., Kwasny M.J., et al. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013, 15:194-202.
2. Gheorghiade M., Böhm M., Greene S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309:1125-1135.
3. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEngl J Med 2013, 369:1317-1326. SAVOR-TIMI 53 Steering Committee and Investigators.
4. Blecker S., Paul M., Taksler G., Ogedegbe G., Katz S. Heart failure associated hospitalizations in the United States. JAm Coll Cardiol 2013, 61:1259-1267.
5. Gheorghiade M., Vaduganathan M., Fonarow G.C., Bonow R.O. Rehospitalization for heart failure: problems and perspectives. JAm Coll Cardiol 2013, 61:391-403.
6. Metra M., Zacà V., Parati G., et al. Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. Heart Failure Study Group of the Italian Society of Cardiology. JCardiovasc Med (Hagerstown) 2011, 12:76-84.
7. Nieminen M.S., Brutsaert D., Dickstein K., et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006, 27:2725-2736.
8. Greenberg B.H., Abraham W.T., Albert N.M., et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007, 154:e271-e278.
9. Kapoor J.R., Fonarow G.C., Zhao X., Kapoor R., Hernandez A.F., Heidenreich P.A. Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. Am Heart J 2011, 162:480-486.e3.
10. MacDonald M.R., Petrie M.C., Varyani F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008, 29:1377-1385.
11. Gustafsson I., Brendorp B., Seibaek M., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. JAm Coll Cardiol 2004, 43:771-777.
12. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004, 27:1879-1884.
13. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668-2673.
14. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patient with stable chronic heart failure. JAm Coll Cardiol 2005, 46:1019-1026.
15. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010, 90:207-258.
16. Cherian S., Lopaschuk G.D., Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012, 303:E937-E949.
17. Rajabi M., Kassiotis C., Razeghi P., Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007, 12:331-343.
18. Metzler B., Schocke M.F., Steinboeck P., et al. Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. JCardiovasc Magn Reson 2002, 4:493-502.
19. Malhotra A., Sanghi V. Regulation of contractile proteins in diabetic heart. Cardiovasc Res 1997, 34:34-40.
20. Teshima Y., Takahashi N., Saikawa T., et al. Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase and ryanodine sensitive Ca(2+)channel mRNA in streptozotocin-induced diabeticrat heart. JMol Cell Cardiol 2000, 32:655-664.
21. Gawlowski T., Stratmann B., Stork I., et al. Heat shock protein 27 modification is increased in the human diabetic failing heart. Horm Metab Res 2009, 41:594-599.
22. Givertz M.M., Sawyer D.B., Colucci W.S. Antioxidants and myocardial contractility: illuminating the "Dark Side" of beta-adrenergic receptor activation?. Circulation 2001, 103:782-783.
23. Metra M., Cotter G., Gheorghiade M., Dei Cas L., Voors A.A. The role of the kidney in heart failure. Eur Heart J 2012, 33:2135-2142.
24. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalised with heart failure. JAm Coll Cardiol 2004, 43:61-67.
25. Solini A., Penno G., Bonora E., et al. Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012, 35:143-149.
26. Jackson C.E., Solomon S.D., Gerstein H.C., et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009, 374:543-550. CHARM Investigators and Committees.
27. Butler J., Fonarow G.C., Gheorghiade M. Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. JAMA 2013, 310:2035-2036.
28. Haas S.J., Vos T., Gilbert R.E., et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003, 146:848-853.
29. Domanski M., Krause-Steinrauf H., Deedwania P., et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. JAm Coll Cardiol 2003, 42:914-922.
30. Deedwania P.C., Giles T.D., Klibaner M., et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005, 149:159-167.
31. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival(COPERNICUS) study. Circulation 2002, 106:2194-2199.
32. Erdmann E., Lechat P., Verkenne P., Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001, 3:469-479.
33. Torp-Pedersen C., Metra M., Charlesworth A., et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007, 93:968-973.
34. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 62:1495-1539.
35. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. NEngl J Med 1991, 325:293-302.
36. Moyé L.A., Pfeffer M.A., Wun C.C. Uniformity ofcaptopril benefit in the SAVE study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994, 15(Suppl B):2-8. 26-30.
37. Gustafsson I., Torp-Pedersen C., Køber L., Gustafsson F., Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. JAm Coll Cardiol 1999, 34:83-89.
38. Borghi C., Ambrosioni E., Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Cardiol 1996, 78:317-322.
39. Ryden L., Armstrong P.W., Cleland J.G., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000, 21:1967-1978.
40. Carr A.A., Kowey P.R., Devereux R.B., et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005, 96:1530-1536.
41. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
42. Cohn J.N., Tognoni G. Arandomized trial of theangiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001, 345:1667-1675.
43. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEngl J Med 2003, 348:1309-1321.
44. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation study investigators. NEngl J Med 1999, 341:709-717.
45. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren fortype 2 diabetes. NEngl J Med 2012, 367:2204-2213.
46. Maggioni A.P., Greene S.J., Fonarow G.C., et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013, 34:3117-3127.
47. von Bibra H., Hansen A., Dounis V., Bystedt T., Malmberg K., Rydén L. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 2004, 90:1483-1484.
48. Basal insulin and cardiovascular and other outcomes in dysglycemia. NEngl J Med 2012, 367:319-328. The ORIGIN Trial Investigators.
49. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358:2560-2572.
50. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med 2008, 358:2545-2559. Action to Control Cardiovascular Risk in Diabetes Study Group.
51. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135. RECORD Study Team.
52. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients withtype 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289. PROactive investigators.
53. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEngl J Med 2013, 369:1327-1335. EXAMINE Investigators.
54. Monami M., Dicembrini I., Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure:a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014, 24:689-697.